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Protease-activated receptors (PARs) are G protein–coupled receptors (GPCRs) that transmit cel-lular responses begun by the actions of extracellular proteases. The activation of a PAR occurs by 
a unique mechanism whereby the extracellular N-terminal segment of the inactive receptor undergoes 
proteolytic cleavage, resulting in irreversible activation––unlike most GPCRs that are reversibly acti-
vated. PARs mediate cellular responses to coagulant proteases in various cell types localized within 
the vasculature. Additionally, PARs are expressed in other cell types and respond to a plethora of 
proteases. Recent studies have revealed that different proteases elicit distinct responses through the 
activation of the same PAR. This phenomenon appears to involve stabilization of distinct active PAR 
conformations that facilitates selectively coupling to different effectors and is localized to caveolae, a 




The four protease-activated receptors (PARs) constitute a fam-
ily of G protein–coupled receptors (GPCRs) that elicit cellular 
responses to extracellular proteases. PARs are expressed in many 
cell types, including cells associated with the vasculature, and are 
best known for mediating responses to coagulant proteases such as 
thrombin (1). PARs mediate hemostasis and thrombosis, inflamma-
tion, vascular development, and cancer progression (2). In addi-
tion to coagulant proteases, several other proteases activate PARs 
in vitro and may modulate their activity in vivo to regulate various 
physiological processes in normal and pathological disease states. 
Specific protease-dependent activation of PARs can differentially 
regulate cellular responses (3–5) by coupling to multiple effectors. 
The finding that distinct proteases can differentially activate PAR 
signaling has added a new level of complexity to PAR signaling. 
Moreover, the mechanisms responsible for mediating protease-
selective PAR signaling are largely unknown. 
The observation that different ligands acting at the same 
receptor can elicit distinct signaling responses has been reported 
for many GPCRs and is a process termed “functional selectivity” or 
“biased agonism” (6). The molecular basis of functional selectively 
involves ligand-induced stabilization of distinct active receptor 
conformations. New studies indicate that compartmentalization of 
GPCRs within membrane microdomains also facilitate stabilization 
of distinct active receptor conformations and promote receptor 
coupling to specific signaling effectors (7). The unique irrevers-
ible mechanism of PAR activation, which results from cleavage of 
its N-terminal domain at a specific site, suggested that PARs are 
activated by only one ligand 
and confounded the concept 
that proteases were capable of 
displaying biased agonism at 
PARs. Our recent study now 
reveals that compartmentaliza-
tion of PAR1 in caveolae is 
critical for protease-selective 
activation and signaling (5). 
Here, we discuss PAR activa-
tion, signaling, and protease-
selective biased agonism. 
The Family of PARs
The four PARs, encoded by 
distinct genes, are a unique 
class of GPCRs that signal in 
response to extracellular pro-
teases. The discovery of PAR1 
in 1991 resulted from a search 
for a receptor that conferred 
thrombin signaling and was 
originally dubbed the “thrombin receptor” (8). PAR1 is considered 
the family prototype and is the predominant mediator of thrombin 
signaling in most cell types. PAR3 and PAR4 were later discovered 
and also shown to elicit cellular responses to thrombin (9–11). 
PAR2 was identified in a mouse genomic library screen using 
probes similar in sequence to the transmembrane regions of the 
substance K receptor (12). Unlike other PARs, PAR2 is activated by 
trypsin-like serine proteases but not by thrombin. 
Thrombin, the main effector protease of the coagulation 
cascade, drives fibrin deposition and signals through PARs to 
promote platelet activation, which is critical for hemostasis and 
thrombosis (1). Activation of PARs by thrombin also contributes 
to inflammatory and proliferative responses triggered by vascu-
lar injury and thrombotic disease. PARs are expressed primar-
ily in cells of the vasculature, including platelets, immune cells, 
endothelial cells, fibroblasts, and smooth muscle cells, and exhibit 
species-specific differences in expression patterns. PAR1 and PAR4 
are the functional thrombin receptors present on human plate-
lets (13), whereas PAR3 and PAR4 mediate thrombin signaling 
in murine platelets (10, 14). In human endothelial cells, PAR1 is 
predominantly expressed together with PAR3 (15), whereas PAR4 
is co-expressed with PAR1 in murine endothelial cells (16). PAR2 
is widely distributed and expressed in endothelial cells, fibroblasts, 
intestinal epithelial cells, and airway cells, mediating inflammatory 
and proliferative responses associated with tissue injury (17). PAR1 
and PAR2 are also expressed in sensory neurons and glial cells and 
initiate neurogenic inflammation, edema and hyperalgesia, how-
ever, the proteases that activate PARs in these particular cell types 
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Figure 1. Proteases and peptide agonists display biased agonism at protease-activated receptor 1 (PAR1). PAR1 
is a seven-transmembrane G protein–coupled receptor activated by a unique proteolytic mechanism. Thrombin (α-Th), a 
serine protease, binds to and proteolytically cleaves the N terminus of PAR1, unmasking a new N terminal domain that 
then acts as a tethered ligand, binding intramolecularly to the body of the receptor to trigger transmembrane signaling. 
Thrombin-activated PAR1 preferentially couples to G12/13 proteins, which signal to RhoGEFs and result in RhoA activa-
tion and endothelial permeability. Synthetic peptide agonists that mimic the newly exposed N terminus–tethered ligand 
domain, SFLLRN, can activate PAR1 independently of proteolysis. Activation of PAR1 by addition of agonist peptides, 
SFLLRN or TFLLRNPNDK, promotes preferential coupling to Gq over G12/13. Activated protein C (APC), an anti-coagulant 
serine protease, requires endothelial protein C receptor (EPCR) as a co-factor and cleaves and activates PAR1. However, 
in contrast to thrombin, activation of PAR1 by APC promotes endothelial barrier protective signaling predominantly 
through Gi coupling and is dependent on caveolae, a subtype of lipid rafts. 
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of coagulant proteases and vascular cells, the particular proteases 
that function as the physiological regulator of PAR activation in a 
given tissue or cellular setting are not well defined. 
Activation and Signaling By PARs 
The model for proteolytic activation of PARs posits that proteases 
cleave a specific peptide bond within the N terminus of the recep-
tor, which results in the formation of a new N terminus that acts 
like a tethered ligand by binding intramolecularly to the receptor 
to trigger transmembrane signaling (Figure 1) (8, 19). Synthetic 
peptides that mimic the tethered ligand sequence of the newly 
exposed N terminus can activate PARs independent of proteolytic 
cleavage, with the exception of PAR3 (9). Although typically pro-
teolytic cleavage leads to activation of the same receptor, there is 
evidence of crosstalk between different PARs. In murine platelets 
and transfected cells, PAR3 binds to and localizes thrombin to 
facilitate activation of PAR4, a low affinity thrombin receptor (20). 
PAR3 is efficiently cleaved by thrombin, but is less efficacious than 
other PARs at eliciting G protein–dependent cellular responses in 
vascular cells. Recent work indicates, however, that activation of 
PAR3 by thrombin induces rapid Ca2+-dependent release of ATP 
from lung epithelial A549 cells, a cell line that does not express 
detectable PAR1 or PAR4 (21). 
Formation of heterodimers
In addition, PAR3 dimerizes with PAR1 and consequently potenti-
ates thrombin signaling in endothelial cells, suggesting that PAR3 
functions as an allosteric modulator of PAR1 signaling in certain 
cell types (22). Another type of PAR crosstalk occurs in endothe-
lial cells, where the tethered ligand domain of signaling-defective 
cleaved PAR1 containing a mutation in a critical proline residue 
in the second extracellular loop region important for receptor 
activation, transactivates PAR2 (15), although the physiological 
significance of this type of intermolecular transactivation remained 
elusive. During the progression of sepsis, a systemic inflammatory 
condition characterized by disseminated intravascular coagula-
tion, activated PAR1 switches from endothelial-disruptive signal-
ing (Box 1) to protective signaling via transactivation of PAR2, a 
receptor whose expression increases in endothelial cells during 
severe sepsis (23). Thus, the formation of heterodimeric complexes 
between PARs appears to modulate certain signaling responses but 
is unlikely to be critical for monomeric PAR coupling to heterotri-
meric G-protein signaling (24). Distinct PAR dimeric complexes, 
however, might have other functions such as facilitating distinct 
protease-selective signaling, but this remains to be determined. 
Signaling effectors
Once activated, PARs undergo conformational changes that 
facilitate their coupling to heterotrimeric G proteins. Activated 








and promotes diverse cellular 
responses (Figure 1). Several early studies indicated that PAR1 
accomplishes this by inhibiting cAMP accumulation through G
i
 
and stimulating phospholipase C (PLC)-catalyzed hydrolysis of 
phosphoinositides (PI) and Ca2+ mobilization through G
q
 (25–27), 
whereas activating the extracellular signal-regulated protein kinases 




 signaling (28). Other 
studies have illustrated coupling of PAR1 to G
12/13
, which leads to 
activation of Rho GEFs, induction of cytoskeletal changes, and PLC 







. Previous studies questioned whether PAR3 is capable of sig-
naling autonomously (20); however, new work indicates that PAR3 
can elicit thrombin-dependent cellular responses in particular cell 
types (21). Although there is no direct evidence linking PAR2 to 
heterotrimeric G-protein activation, numerous studies demonstrate 
that activation of PAR2 with proteases and/or synthetic peptide 





 and perhaps G
12/13 
signaling. Activated PAR2 also binds to and 
internalize with β-arrestin, a multifunctional adaptor protein (32, 
33). Once internalized, the PAR2-β-arrestin complex functions as 
a scaffold to recruit ERK1,2 on endocytic vesicles and is thought 
to sustain ERK1,2 signaling in the cytoplasm independently of 
G-protein activation. The activation of distinct G-protein subtypes 
as well as non-G-protein effectors by PARs is crucial for eliciting 
cell type-specific responses. The extent to which PARs couples to 
distinct G-protein subtypes in a particular cell type depends in part 
on the G-protein and effector repertoire expressed in the cells but 
other mechanisms are likely to exist. 
Box 1. Endothelial Barrier Integrity and 
Permeability
Vascular endothelial cells line blood vessels and 
maintain blood fluidity and endothelial barrier 
integrity. Most resting endothelial cells in non-injured 
tissues form tight junctions creating an endothelial 
barrier, which prevents plasma proteins from mov-
ing into interstitial tissues. The formation of the 
endothelial barrier is mediated by adherens junc-
tions, which facilitate stable cell-cell interactions. The 
disruption of the endothelial barrier involves intracel-
lular signaling events that lead to disassembly of 
adherens junctions and reorganization of the actin 
cytoskeleton and dissolution or loosening of cell-cell 
interactions. This results in an increase in endothelial 
barrier permeability. Restoration of endothelial bar-
rier involves a different type of intracellular signaling 
that promotes re-formation of adherens junctions and 
formation of tight cell-cell interactions.
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Multiple proteases  
activate PAR signaling
In addition to thrombin, other 
proteases activate PAR1. Tissue 
factor (TF), a single transmem-
brane protein, initiates coagula-
tion by generating thrombin 
through activation of coagulation 
factor (F) VIIa and FXa and also 
promotes cellular signaling via 
activation of PARs. The upstream 
coagulation protease FXa can, 
by itself, proteolytically cleave 
and directly activate PAR1 or 
do so in a complex with TF 
and FVIIa (34, 35). Activated 
protein C (APC), when bound 
to endothelial protein C recep-
tor (EPCR), a single spanning 
transmembrane protein, cleaves 
and inactivates FVa and VIIa to 
diminish thrombin generation 
and induces cellular responses 
through the activation of PAR1 
(Figure 1) (36). APC, an anti-
coagulant protease, is generated 
on the endothelial cell surface 
via activation of protein C (PC) by the complex composed of 
thrombin and thrombomodulin, an integral membrane protein 
that allosterically modulates thrombin’s enzymatic activity to favor 
PC activation (37). Plasminogen, a plasma-enriched zymogen, 
is cleaved by urokinase and tissue plasminogen activator (TPA) 
to generate the active enzyme plasmin, which degrades fibrin. 
Plasmin also cleaves PAR1 at multiple sites, which either activates 
or incapacitates the receptor, depending on the cleavage site (38, 
39). More recently, matrix metalloproteinase-1 (MMP-1), also 
known as interstitial collagenase, was shown to activate PAR1 in 
invasive breast carcinoma, but precisely how MMP-1 acts on PAR1 
to generate a functional ligand and/or cellular signaling has not 
been clearly established (40). 
Several proteases can activate PAR2, including trypsin, FVIIa 
in complex with TF and FXa, neutrophil protease-2, mast cell 
tryptase, membrane-tethered serine protease-1 and others but not 
thrombin (17). The TF-FVIIa complex can activate PAR2 either 
directly as a binary complex or indirectly through generation of 
FXa. FXa may signal more efficiently in a ternary complex with 
TF-VIIa than it does as a monomer. Ahamed et al. showed that 
a TF-VIIa complex containing a distinct “cryptic” form of TF in 
which a specific disulfide bond is reduced fails to support coagu-
lation (i.e., thrombin generation) but retains its ability to signal 
via PAR2 (41). It has not been determined, however, whether 
activation of PAR2 by TF-VIIa or the TF-VIIa-Xa complex pro-
mote distinct cellular responses and hence, shed doubt on the 
physiological relevance of these findings (42). Similar to other 
PARs, PAR2 is modified by N-linked glycosylation, a process that 
affects activation of PAR2 by tryptase but not by trypsin nor syn-
thetic peptide agonists (43). Mutants of PAR2 in which the teth-
ered ligand sequence SLIGRL was changed to SLAAA or SAIGRL 
displayed robust increases in Ca2+ mobilization when activated 
proteolytically by trypsin or by addition of SLIGRL synthetic pep-
tide to unproteolyzed mutant PAR2 (44). However, when added 
exogenously to cells in culture, neither SLAAA nor SAIGRL syn-
thetic peptides could elicit cellular responses comparable to those 
obtained with SLIGRL, the native tethered ligand sequence. These 
findings suggest that the cleavage event itself (which may elicit 
a conformational change) rather than unmasking of the ligand 
sequence is critical for PAR2 activation, whereas other structural 
determinants maybe required for activation of PAR2 by synthetic 
peptide agonists. The differences in signaling potential between 
the tethered ligand and exogenously added synthetic peptides are 
not clearly understood and may not be simply due to differences 
in the off rate of the two ligands.
Similar to other PARs, PAR4 is cleaved and activated by mul-
tiple serine proteases including thrombin, trypsin, plasmin, and 
cathepsin G (1). Both the kinetics of PAR4 activation and shut-off 
Table 1. Characteristics of the Four Protease-Activated Receptors
Receptor Tethered ligand Activating proteases Signaling 
effectors
Shut-off mechanisms







































1Synthetic peptides that represent the newly formed N terminus can activate PARs independent of protease and cleavage 
with the exception of PAR3. 2Shut-off mechanisms are best understood for PAR1 and PAR2, whereas activated PAR4 is not 
phosphorylated and its shut-off appears to mediated predominantly by internalization. Nothing is known about signal regu-
lation of PAR3. 
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of signaling responses are slow, resulting in sustained signaling, in 
marked contrast to other PARs (45, 46); mechanistically how this 
occurs is not known. In addition, the signaling effectors and cell-
type specific responses triggered by activated PAR4 remain poorly 
characterized. Besides thrombin, it remains to be determined 
whether other proteases are capable of proteolytically activating 
PAR3, a receptor that displays autonomous signaling (i.e., capable 
of signaling without input from other receptors) only in certain cell 
types. Clearly, many different proteases cleave and activate PARs, 
however, whether these proteases stabilize distinct active PAR con-
formations to promote coupling to specific signaling effectors and 
cell-type specific responses has not been thoroughly investigated. 
Nonetheless, new studies have revealed that activation of PAR1 by 
two different proteases promotes distinct cellular signaling, a phe-
nomenon termed functional selectivity or biased agonism (6).
PAR1 Displays Biased Agonism
The finding that different ligands are capable of promoting distinct 
signaling responses through the activation of the same receptor 
has now been reported for many GPCRs (6). In many cases, dif-
ferences in signaling have been observed in studies comparing 
synthetic ligands to natural ligands, questioning the physiologi-
cal significance of such findings. Indeed, early studies suggested 
that distinct cellular responses could be evoked by PAR1 when 
activated proteolytically by its tethered ligand versus activation 
by untethered “free” synthetic peptide agonists (Figure 1) (6, 47). 
More recently, McLaughlin et al. demonstrated in human endothe-
lial cells that activation of PAR1 with thrombin favors G
12/13 
signal-
ing and induction of endothelial barrier permeability rather than 
G
q
-dependent Ca2+ mobilization (48). In contrast, synthetic PAR1 
peptide agonists SFLLRN and TFLLRNPNDK caused preferential 
activation favoring G
q
-triggered increases in Ca2+ mobilization 
rather than G
12/13 
signaling, but whether different endogenous pro-
teases promote distinct signaling through the activation of PARs 
remained an open question. 
Several recent studies have now reported that two different 
proteases, thrombin and activated protein C (APC), cleave and 
activate PAR1 but cause opposite effects on endothelial barrier 
permeability (Figure 2) (3, 4). In general, thrombin functions as 
a pro-inflammatory mediator and disrupts endothelial barrier 
permeability through the activation of PAR1 (49). In contrast to 
thrombin, however, activation of PAR1 by APC elicits anti-inflam-
matory responses and promotes endothelial barrier stabilization 
(3, 4). APC is generated on the endothelial cell surface where it is 
poised to signal via direct activation of PAR1 (36, 50). The cyto-
protective and anti-inflammatory responses induced by APC also 
require the co-factor function of EPCR (36). Moreover, APC reduc-
es mortality of patients with severe sepsis (51), but the molecular 
mechanisms by which APC distinctly activates PAR1 signaling are 
not clearly understood.
Proteolytic activation of PAR1 requires unmasking of a teth-
ered ligand that binds intramolecularly to the body of the receptor 
stabilizing an active receptor conformation that triggers transmem-
brane signaling. Although APC has the capacity to cleave PAR1, it 
does so with considerably less efficiency than does thrombin (52). 
Thus, the extent of PAR1 activation by APC should be different 
than thrombin, which efficiently cleaves the receptor. Whether 
APC cleavage of PAR1 is the only critical determinant that facili-
tates PAR1 selective signaling and endothelial barrier protection 
is not known. If cleavage of PAR1 by APC is solely responsible 
for endothelial barrier–protective signaling, then quantitative, not 
qualitative, differences in signaling would be observed following 
activation of PAR1 by thrombin versus APC. To test this possibility, 
we recently examined the effect of thrombin and APC on the acti-
vation of RhoA and Rac1, small GTPases that differentially regulate 
endothelial barrier permeability (Figure 2). Thrombin and APC 
signaling were lost in PAR1-deficient endothelial cells, indicating 
that PAR1 is the major effector for protease signaling in these cells 
(5). We also found that thrombin caused robust RhoA signal-
ing but not Rac1 activation, whereas APC stimulated a marked 
increase in Rac1 activation but not RhoA signaling, consistent with 
the opposing functions of these proteases on endothelial barrier 
integrity (5). Thus, the activation of PAR1 by APC likely results 
in a distinct active receptor conformation that selectively couples 















Figure 2. Caveolae are required for APC-mediated but not thrombin-
mediated activation of PAR1 signaling. Thrombin (α-Th) activates RhoA 
but not Rac1 signaling and promotes endothelial barrier permeability. PAR1 
is essential for thrombin –induced endothelial cellular responses but does not 
require caveolae for signaling. EPCR the co-factor for APC, PAR1, and G pro-
teins associate with caveolin-1, a structural component essential for caveolae 
formation. In contrast to thrombin, APC activates PAR1 and induces robust 
Rac1 signaling but not RhoA activation, to promote endothelial barrier protec-
tion. The expression of PAR1 is required for APC cellular signaling. Moreover, 
APC activation of PAR1 barrier protective signaling requires compartmental-
ization in caveolae. 
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Membrane Microdomains and Protease-
Dependent Biased Agonism
How can activation of the same receptor by two different proteases 
elicit distinct cellular responses? The underlying mechanisms 
that regulate coupling of proteolytically activated PAR1 to distinct 
signaling effectors involve localization to caveolae, a specific type 
of plasma membrane microdomain (Figure 2). Caveolae are lipid 
rafts enriched in cholesterol and caveolins and function as micro-
domains that facilitate receptor-effector coupling and signal trans-
duction. Indeed, the expression of caveolin-1 is essential for APC 
but not for thrombin activation of PAR1 signaling and endothelial 
barrier protection (5), suggesting that PAR1 localization to cave-





 partition into lipid rafts and may exist as 
a preassembled complex that associates with caveolin-1 (53–55), 
a structural protein essential for caveolae formation in endothelial 
cells (56). The barrier protective signaling induced by APC is also 
blocked by pertussis toxin, suggesting a role for G
i/o 
in this process 
(54). Moreover, the localization of APC bound to EPCR in lipid 
rafts facilitates efficient PAR1 cleavage and activation, suggest-
ing that caveolae localization stabilizes a distinct active receptor 
conformation that elicits barrier protective signaling (57). Taken 
together, these data suggest that PAR1 colocalization with EPCR 
and G
i/o
 proteins in caveolae facilitates activation by APC. In con-
trast, caveolin-1 is not essential for thrombin activation of PAR1 
signaling (5), indicating that caveolin-1 only modulates PAR1 
signaling when selectively activated by APC in endothelial cells. 
This finding does exclude the possibility that thrombin activates 
PAR1 localized to caveolae but its cellular consequences are not 
known. Carlie-Klusacek and Rizzo have identified a function for 
lipid rafts but not for caveolae in thrombin-induced changes to 
the cytoskeleton of endothelial cells, a cellular process controlled 
predominantly by G
12/13 
signaling (58). Moreover, caveolae are also 
required for TF-VIIa-mediated but not for peptide agonist–medi-
ated activation of PAR2; but whether TF-VIIa, agonist peptide, 
or trypsin promote distinct cellular signaling responses was not 
examined (59).
The molecular determinants that specify the targeting of 
PAR1 and signaling components to caveolae are largely unknown 
but may involve post-translational modifications. Caveolin-1 is 
palmitoylated and together with cholesterol and sphingolipids 
form caveolar microdomains, which sequester other lipid-modified 
proteins within the plasma membrane. A large number of GPCRs 
appear to be modified by palmitoylation, which occurs through 
the covalent attachment of a C16 fatty-acid chain via a thioester 
linkage to cysteine residues localized within the cytoplasmic tail of 
the receptor. PAR1 and PAR2 have cytoplasmic cysteine residues 
that could serve as sites for palmitoylation, but, to our knowledge, 
this has not been reported. Palmitoylation of tissue factor (TF) is 
known to facilitate its localization to caveolae and to prevent pro-
tein kinase C–dependent phosphorylation, a process that controls 
tissue factor pro-coagulant activity (60). Thus, the modulation 
of TF with palmitoylation may facilitate localization of TF-FVIIa 
and Xa with PAR2 in caveolar microdomains to promote cellular 
signaling. Whether EPCR is similarly palmitoylated is not known. 
Several studies, however, do suggest that protein palmitoylation 
protects proteins from ubiquitination and subsequent degrada-
tion (61, 62). Both PAR1 and PAR2 are ubiquitinated (63, 64), but 
whether PAR ubiquitination facilitates receptor palmitoylation or 
targeting of proteins to caveolae has not been examined. 
In addition to post-translational modifications, recent work 
suggests that localization of the µ-opiate receptor (MOR) to lipid 
rafts is regulated by its interaction with the heterotrimeric G
i2
 
protein [(7), see also (65)]. The localization of MOR to lipid rafts 
is disrupted by cholesterol depletion as well as by altering the 
expression of G
i2
. In the absence of agonist, MOR directly associ-
ates with G
i2
 via a G protein-interaction motif. Upon deletion of 
this motif, the receptor leaves the lipid microdomain. Etorphine 
promotes MOR interaction with β-arrestin, which, in turn, facili-
tates receptor translocation out of the lipid raft––a process that 
required receptor dissociation from G
i2
. By contrast, stimulation 
of MOR with morphine induces an activate receptor conforma-
tion that preferentially binds to G
i2
 and shows a low affinity for 
β-arrestin, consistent with minimal receptor phosphorylation and 
lack of internalization. Thus, membrane microdomain association, 
and interaction with heterotrimeric G
i2
 protein regulates agonist-
selective signaling by MOR. Whether PAR1 interaction with G
i2
 is 
important for caveolae association and protease-selective signaling 
will be important to determine. 
The expression of β-arrestin-2 is also critical for maintain-
ing distinct assemblies of the G protein–coupled serotonin 2A 
receptor (5-HT2AR) with signaling effectors (66). The ablation of 
β-arrestin-2 expression causes selective loss of responses to the 
endogenous ligand serotonin, but not to a distinct synthetic ligand 
2,5-dimethoxy-4-iodoamphetamine (DOI) (66). Caveolin-1 also 
interacts with 5-HT2AR and modulates the capacity of 5-HT2AR 
to couple to G
q
 signaling (67). Whether β-arrestin affects 5-HT2AR 
localization to lipid rafts was not evaluated. 
Protease-Selective Mechanisms of PAR 
Desensitization
The ability of different ligands to promote distinct signaling 
responses through the activation of the same receptor suggests 
that unique active receptor conformations can be induced. These 
findings raise intriguing questions regarding the mechanisms 
that mediate desensitization of distinctly activated GPCRs. In the 
classic paradigm, activated GPCRs are initially desensitized via 
rapid phosphorylation by G protein–dependent kinases (GRKs) 
(68). Phosphorylation enhances receptor affinity for arrestin, and 
arrestin binding prevents receptor-G-protein interaction, thereby 
uncoupling the receptor from signaling. Arrestin also interacts 
with components of the endocytic machinery to facilitate GPCR 
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internalization, thereby removing activated receptors from signal-
ing effectors at the plasma membrane. Within endosomes, the 
receptors dissociate from their ligands, become dephosphorylated, 
and then return to the cell surface in a state capable of respond-
ing to ligand again. Several recent studies indicate that GPCRs 
activated by different ligands are desensitized through distinct 
mechanisms (69). 
Desensitization of the µ-opioid receptor (MOR) following acti-
vation by morphine occurs predominantly through protein kinase 
C–dependent phosphorylation, whereas DAMGO activated MOR 
phosphorylation is largely dependent on GRK. Activation of the 
CC chemokine receptor 7 (CCR7) with the endogenous chemokine 
CCL19, on the other hand, induces robust phosphorylation and 
arrestin-dependent desensitization (70). In contrast, a different 
endogenous ligand, CCL21, fails to promote phosphorylation or 
arrestin-dependent desensitization of activated CCR7, suggesting 
that different ligands induce distinct desensitization of CCR7. 
The desensitization of PAR1 signaling is controlled by mul-
tiple regulatory mechanisms. The first involves agonist-induced 
PAR1 phosphorylation and the second involves interaction with 
β-arrestin. Signaling by PAR1, however, appears to be more 
effectively regulated by β-arrestin-1 rather than by β-arrestin-2, 
through a process that does not require receptor phosphorylation 
(71, 72). Additionally, activated PAR1 internalization and lysosom-
al degradation are also required for termination of receptor signal-
ing (73), whereas activated 
PAR1 internalization occurs 
independent of arrestins (72). 
Whether desensitization of 
PAR1 differs when activated 
proteolytically by thrombin 
versus synthetic peptide ago-
nists has not been rigorously 
examined. We recently found 
that APC promotes PAR1 
phosphorylation and desensi-
tization but causes negligible 
receptor internalization and 
degradation (Figure 3) (5). We 
have not determined whether 
thrombin- versus APC-
activated PAR1 is differentially 
phosphorylated and whether 
distinct kinases mediate this 
process. 
Conclusions
PARs are activated by prote-
olytic cleavage, resulting in 
irreversible activation, unlike 
most GPCRs that are reversibly 
activated. The temporal and spatial regulation of PAR signaling is 
crucial for a variety of physiological responses that include vascu-
lar integrity, proper growth, and cellular migration. Activated PARs 
couple to multiple effectors and promote diverse cellular respons-
es. In addition to coagulant proteases, several other proteases 
can cleave and activate PARs. In most cases, the signaling and 
cell type–specific responses elicited by different proteases remain 
poorly understood. That different proteases activate the same PAR 
but elicit distinct cellular responses (5) adds a new level of com-
plexity to understanding PAR signaling and its functions in various 
tissues and cell types. Whether different proteases cleave PARs at 
the same or different sites to yield distinct unmasked ligands that 
elicit distinct cellular responses is not known. Moreover, whether 
the interaction of different proteases with PARs also contributions 
to functional selectivity remains to be determined. We will now 
need to further explore whether different proteases acting on the 
same PAR elicit distinct responses by evaluating multiple signal-
ing effectors activated through distinct heterotrimeric G-protein 
subtypes as well as through non-G-protein dependent effectors. 
The mechanisms responsible for desensitization of PARs by differ-
ent proteases have yet to be fully elucidated and are also vital to 
our understanding of protease signaling. Fundamental questions 
regarding the mechanisms by which different proteases distinctly 
activate PARs also remain. 
The studies reported thus far, provide strong evidence that 
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Figure 3. Differentially activated PAR1 is regulated by distinct mechanism. Thrombin, APC, and peptide agonists 
promote distinct PAR1 signaling in endothelial cells, suggesting that distinct active receptor conformations are induced. 
The mechanisms responsible for PAR1 desensitization following activation by distinct proteases appears be different. 
Activation of PAR1 by thrombin, peptide agonist, and APC promote rapid and robust receptor phosphorylation, an event 
critical for uncoupling PAR1 from G-protein signaling. The kinases that mediate PAR1 phosphorylation and PAR1 phos-
phorylation sites induced by the distinct ligands, however, have not been thoroughly examined. Moreover, thrombin and 
peptide agonist but not APC promotes PAR1 internalization, suggesting that the different active receptor conformations 
have the capacity to differentially engage the endocytic machinery. The role of arrestins or other endocytic adaptors pro-
teins in regulating distinctly activated PAR1 internalization has not been examined.
94
Review
different proteases can activate the same PAR to elicit distinct 
signaling responses, suggesting that different drugs could be devel-
oped to target PAR signaling selectively. The ability to fine-tune 
PAR signaling by either activating or inhibiting specific signaling 
pathways could enhance therapeutic efficacies and also minimize 
undesirable side effects. Thus, a better understanding of how dif-
ferent proteases distinctly activate PAR signaling is crucial for drug 
development.  doi:10.1124/mi.9.2.8
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